Boston Heart Diagnostics
Tara Perrin has a diverse work experience spanning various roles in the healthcare industry. Tara is currently working as an Area Sales Manager at Boston Heart Diagnostics since October 2022. Prior to this, from March 2019 to October 2022, they worked as a Territory Sales Manager at Genova Diagnostics. Tara'sresponsibilities included managing sales territories and promoting diagnostic products.
From August 2015 to December 2018, Tara worked as an Immunology Specialist at Syneos Health - Janssen Biotech. In this role, they launched a new indication for a specialty biologic and sold a portfolio of drugs to the Gastroenterology market.
Before that, Tara worked at Seabrook House from January 2014 to August 2015 as a Clinical Outreach representative. Tara excelled at building a database of healthcare providers and educating them on addiction treatment.
Prior to that, they served as a Regional Manager at Vitality Healthcare from May 2009 to January 2014. Tara led a team of sales representatives and focused on bridging the gap in healthcare by providing orthopedic bracing and genetic testing.
Tara's early work experience includes their role as a Durable Medical Equipment Sales Representative at Medical Finance Resources Inc from August 2001 to May 2009. Tara was responsible for prospecting, building new business, and providing customer support.
Overall, Tara Perrin has a strong background in healthcare sales and marketing, with experience in managing sales territories, launching new products, and building relationships with healthcare providers.
Tara Perrin has a BA in Speech Communications from East Stroudsburg University. There is no information available about the specific start and end years of their education.
This person is not in the org chart
This person is not in any offices
Boston Heart Diagnostics
Boston Heart Lab is a healthcare company that provides cardiovascular disease (CVD) management. Through there combination of proprietary lipid testing capability, sophisticated tools, advanced therapy guidelines, and patient support services, they are providing physicians, patients, and pharmaceutical companies with viable disease management.Unlike other lipid testing companies that are focused on the primary screening market for CVD, their proprietary testing technology allows for the ongoing monitoring of a patient's disease and precise determination of the most appropriate pharmaceutical alternatives. They can provide unique, personalized treatment options to patients with dyslipidemia to determine the efficacy of lipid adjusting drugs in most cases within the first 6 weeks of treatment. Competing methods usually need 6 months.